Kaye A, Perkinson K, Spillers N, Vega A, Roberts C, Downs E
Curr Issues Mol Biol. 2024; 46(11):12746-12755.
PMID: 39590351
PMC: 11592979.
DOI: 10.3390/cimb46110757.
Paulekas E, Vanagas T, Lagunavicius S, Pajediene E, Petrikonis K, Rastenyte D
Biomedicines. 2024; 12(9).
PMID: 39335634
PMC: 11429448.
DOI: 10.3390/biomedicines12092121.
Sade O, Fischel D, Barak-Broner N, Halevi S, Gottfried I, Bar-On D
Front Mol Neurosci. 2024; 17:1431549.
PMID: 39296283
PMC: 11409901.
DOI: 10.3389/fnmol.2024.1431549.
Martins G, Galamba N
J Chem Inf Model. 2024; 64(15):6115-6131.
PMID: 39046235
PMC: 11323248.
DOI: 10.1021/acs.jcim.4c00965.
Abioye A, Akintade D, Mitchell J, Olorode S, Adejare A
Pharmaceutics. 2024; 16(5).
PMID: 38794271
PMC: 11124533.
DOI: 10.3390/pharmaceutics16050609.
Copper ion incorporation in α-synuclein amyloids.
Walke G, Kumar R, Wittung-Stafshede P
Protein Sci. 2024; 33(4):e4956.
PMID: 38511511
PMC: 10955613.
DOI: 10.1002/pro.4956.
Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.
Chiu Y, Wu K, Yu S, Wu K, Wang Y, Lin J
PLoS One. 2023; 18(9):e0291927.
PMID: 37733672
PMC: 10513202.
DOI: 10.1371/journal.pone.0291927.
Amyloids of α-Synuclein Promote Chemical Transformations of Neuronal Cell Metabolites.
Horvath I, Mohamed K, Kumar R, Wittung-Stafshede P
Int J Mol Sci. 2023; 24(16).
PMID: 37629028
PMC: 10454467.
DOI: 10.3390/ijms241612849.
GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms.
Schneider J
Int J Mol Sci. 2023; 24(11).
PMID: 37298133
PMC: 10252733.
DOI: 10.3390/ijms24119183.
Distinct growth regimes of α-synuclein amyloid elongation.
Horvath I, Welte H, Schmit J, Kovermann M, Wittung-Stafshede P
Biophys J. 2023; 122(12):2556-2563.
PMID: 37170496
PMC: 10323017.
DOI: 10.1016/j.bpj.2023.05.009.
Mechanistic Insights into Polyphenols' Aggregation Inhibition of α-Synuclein and Related Peptides.
Martins G, Nascimento C, Galamba N
ACS Chem Neurosci. 2023; 14(10):1905-1920.
PMID: 37125909
PMC: 10197135.
DOI: 10.1021/acschemneuro.3c00162.
Aggregation of Disordered Proteins Associated with Neurodegeneration.
Tsoi P, Quan M, Ferreon J, Ferreon A
Int J Mol Sci. 2023; 24(4).
PMID: 36834792
PMC: 9966039.
DOI: 10.3390/ijms24043380.
Amyloid Fibers of α-Synuclein Catalyze Chemical Reactions.
Horvath I, Wittung-Stafshede P
ACS Chem Neurosci. 2023; 14(4):603-608.
PMID: 36745416
PMC: 9936539.
DOI: 10.1021/acschemneuro.2c00799.
Monitoring α-synuclein aggregation.
Estaun-Panzano J, Arotcarena M, Bezard E
Neurobiol Dis. 2022; 176:105966.
PMID: 36527982
PMC: 9875312.
DOI: 10.1016/j.nbd.2022.105966.
Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective.
Knecht L, Folke J, Dodel R, Ross J, Albus A
Neurotherapeutics. 2022; 19(5):1489-1502.
PMID: 36083395
PMC: 9606184.
DOI: 10.1007/s13311-022-01288-7.
Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer's and Parkinson's Disease.
Gutierrez B, Limon A
Biomedicines. 2022; 10(7).
PMID: 35885050
PMC: 9313353.
DOI: 10.3390/biomedicines10071743.
Crossroads between copper ions and amyloid formation in Parkinson's disease.
Wittung-Stafshede P
Essays Biochem. 2022; 66(7):977-986.
PMID: 35757906
PMC: 9760422.
DOI: 10.1042/EBC20220043.
Dynamics of Amyloid Formation from Simplified Representation to Atomistic Simulations.
Nguyen P, Tuffery P, Derreumaux P
Methods Mol Biol. 2022; 2405:95-113.
PMID: 35298810
DOI: 10.1007/978-1-0716-1855-4_5.
Phosphorylated α-synuclein in diluted human serum as a biomarker for Parkinson's disease.
Chen W, Chen J, Chang S, Chao C, Wu Y, Chen C
Biomed J. 2022; 45(6):914-922.
PMID: 34974168
PMC: 9795354.
DOI: 10.1016/j.bj.2021.12.010.
A Quantitative Perspective of Alpha-Synuclein Dynamics - Why Numbers Matter.
Specht C
Front Synaptic Neurosci. 2021; 13:753462.
PMID: 34744680
PMC: 8569944.
DOI: 10.3389/fnsyn.2021.753462.